Dr. Reddy's Laboratories announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding access to advanced GLP&#8209;1 receptor agonist–based therapy for the management of type 2 diabetes in India. </P> Dr. Reddy's has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company's Day&#8209;1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India. </P>